Merck's Remigromig Hits Primary Endpoint in Diabetic Macular Edema Trial
Merck's investigational tri-specific antibody remigromig has achieved its primary endpoint in a Phase 2b/3 trial for diabetic macular edema. The drug showed non-inferiority to ranibizumab in measuring best-corrected visual acuity change at week 52, with both the 0.5 mg and 0.8 mg doses demonstrating similar results.
The BRUNELLO trial compared remigromig to ranibizumab in adults with diabetic macular edema. While remigromig was generally well-tolerated, the trial results showed higher rates of adverse events among patients receiving remigromig compared to those receiving ranibizumab.
The company plans to discuss the trial results with regulatory authorities and is continuing to evaluate remigromig in ongoing Phase 2b/3 and Phase 2 proof-of-concept studies.